secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0000950170-23-027975
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

BMS terminates collaboration on CC-99712; Sutro regains full rights
-------------------------------------------------------------------

- BMS notified Sutro on June 9, 2023 of termination of Amended Collaboration and License Agreement for CC-99712.
- Termination effective October 7, 2023; decision attributed to BMS portfolio prioritization.
- After termination, Sutro regains sole worldwide rights to the BCMA-targeting antibody-drug conjugate program.
- No financial terms, termination payments, or immediate impact on cash runway disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/stro-20230608.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer